Imunon, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Imunon, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.1 times its market value (net cash). Higher than 90% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 500% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-68.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 77% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -72%In 3 years sales changed by -100% while total assets changed by -72%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-34.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 66% of Healthcare companies in United States.
Cash Cushion Ratio
1.1× cashCash, after subtracting all debt, is 1.1 times its market value (net cash).
Higher than 90% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Imunon, Inc. made a loss over the last year. Imunon, Inc. owes $0.58 for every $1 it owns. Imunon, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossImunon, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.09The share price is 2.09 times Imunon, Inc.'s book value per share, lower than 57% of Healthcare companies in United States.
Market cap
$7 MThe total market value of all of Imunon, Inc.'s shares at today's price (share price × number of shares), smaller than 90% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat Imunon, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.60Net worth divided by the number of shares. The share price of $1.25 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-429.7%Imunon, Inc. lost 429.7% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
0.58×Imunon, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Dividend yield
NoneImunon, Inc. does not currently pay a dividend.
Profit growth
LossImunon, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashImunon, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Imunon, Inc.: $7 M ÷ $3 M (31 Mar 2026) = 2.1.
What is Imunon, Inc.'s return on equity?
Imunon, Inc. lost 429.7% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Imunon, Inc. owe compared with what it owns?
Imunon, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Does Imunon, Inc. pay a dividend?
No. Imunon, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.